

D Alan Anthony

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/332899/publications.pdf>

Version: 2024-02-01

22
papers

5,919
citations

687363

13
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

7939
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies. , 2022, 233, 108028.		8
2	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Journal of Clinical Oncology, 2022, 40, 2048-2057.	1.6	65
3	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. Acta OncolÃ³gica, 2022, 61, 583-590.	1.8	4
4	Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 2022, 10, 745-756.	3.4	22
5	Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. Journal of Gastrointestinal Cancer, 2021, , 1.	1.3	2
6	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	3.7	5
7	Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth. Frontiers in Oncology, 2020, 10, 575148.	2.8	9
8	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. Journal of Clinical Oncology, 2020, 38, 4516-4516.	1.6	20
9	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 1038.	4.3	154
10	A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 2019, 120, 579-586.	6.4	2
11	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529.	4.2	189
12	A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.. Journal of Clinical Oncology, 2019, 37, 3095-3095.	1.6	18
13	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 2018, 118, 947-954.	6.4	30
14	A phase I trial of the Î³-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 793-801.	6.4	90
15	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 2018, 10, .	12.4	288
16	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, The, 2017, 389, 1011-1024.	18.7	1,475
17	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European Journal of Cancer, 2017, 87, 147-163.	2.8	108
18	Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer, 2016, 16, 779.	2.6	3

#	ARTICLE	IF	CITATIONS
19	â€˜Tablet burdenâ€™™ in patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2016, 55, 1-6.	2.8	12
20	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5908-5917.	7.0	38
21	Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. <i>BMC Cancer</i> , 2012, 12, 536.	2.6	7
22	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	27.0	3,370